Compare Gitlab Inc (GTLB) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs Novartis AG — how do they compare? Gitlab Inc trades at $54.42 (market cap $8.92B), while Novartis AG trades at $143.81 (market cap $268.57B). The key difference: Novartis AG is far larger — about 30.1× Gitlab Inc's market cap, and Novartis AG pays a 3.31% dividend while Gitlab Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gitlab Inc for 62 Days and Novartis AG for 82 Days on average.
| GTLB | NVS | |
|---|---|---|
Market Cap | $8.92B | $268.57B |
Volume | 4,716,893 | 1,532,573 |
Sector | Technology | Health |
52-Week High | $53.56 | $168.62 |
52-Week Low | $19.42 | $121.80 |
Typical Hold Time | 62 Days | 82 Days |
Enterprise Value | $7.66B | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab (GTLB) trades at $51.99, up 0.7% on the day and near its 52-week high, supported by a bullish technical outlook and strong Q2 2026 earnings beats. Revenue growth accelerated to 21.3% year-over-year, with the company raising full-year guidance amid robust AI-driven demand for its DevSecOps platform. However, the stock trades at a high P/E ratio of 521.22, reflecting premium valuation despite negative net income margins.
The investment case hinges on GitLab's execution in monetizing AI and enterprise expansion, but risks include sustained profitability challenges and competitive pressure. Analysts are mixed with a Hold consensus, yet recent news highlights sales momentum and institutional interest, suggesting potential upside if growth targets are met.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
